dr eunice wang

Dr. Eunice Wang0:00:31

Dr. Eunice Wang | Spend Just One Day With Us

Decision-Making in AML:0:18:36

Decision-Making in AML: What's Next After Relapse I Dr. Eunice Wang - MRD Status #AML

Eunice Wang, MD,0:00:43

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

Searching for Effective0:04:06

Searching for Effective Treatment in Newly Diagnosed FLT3 Positive AML | Eunice Wang | ASH 2021 #AML

Dr Ravi Vij0:02:26

Dr Ravi Vij MD, is Discussing with Dr. Eunice Wang MD, on Acute Myeloid Leukemia:Targeted Therapies

Dr. Wang on0:01:28

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML

Eunice Wang, MD,0:01:34

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

AML Research and0:01:25

AML Research and Emerging Treatment Options: An Expert’s Perspective

Types of Leukemia0:02:08

Types of Leukemia Treatment at Roswell Park

What Should I0:02:59

What Should I Do if I Have to Find a New Cancer Treatment Provider?

What Key Tests0:09:57

What Key Tests Do You Need Before Choosing an AML Treatment?

Eunice Wang, MD,0:02:05

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Eunice Wang, MD,0:01:24

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

Efficacy of PARP0:02:11

Efficacy of PARP inhibitors in the treatment of AML

Eunice Wang, MD,0:01:25

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

Molecular Targets for0:06:27

Molecular Targets for Personalized Treatment of AML (Acute Myeloid Leukemia)

Targeting AML with0:01:15

Targeting AML with multimodal immunotherapeutic approaches

Eunice S. Wang,0:00:50

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

Eunice Wang, MD,0:03:14

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

Eunice Wang |0:02:38

Eunice Wang | ASCO 2018 | What are the new advances in AML treatment?

Eunice Wang, MD,0:02:05

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

Eunice Wang, MD,0:01:21

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

Gemtuzumab ozogamicin plus0:06:42

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Debating an Algorithm0:05:59

Debating an Algorithm for Molecular Testing in AML